FIELD: biotechnology.
SUBSTANCE: invention relates to recombinant proteins of thrombospondin type I representative of family of proteins CCN and can be used in medicine for treating cancer or fibrosis. Disclosed is a monomeric fusion protein for inhibiting the effect or activity of 4-domain CCN protein, comprising a polypeptide corresponding to at least a portion of a homology domain to repeats of thrombospondin type 1 (TSP-1) of a CCN family protein and a monomer fusion partner fused therewith at the N- or C-terminus, which contains at least 6 amino acids and increases the serum half-life of said fused protein.
EFFECT: invention provides the production of fused proteins based on truncated fragments of domain III of the CCN family protein, which reproduce or have the biological activity of CCN5, are able to antagonize or inhibit effects of 4-domain CCN proteins and are resistant to proteolytic degradation.
21 cl, 16 dwg, 1 tbl, 23 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN | 2018 |
|
RU2813996C2 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
| THERAPEUTIC FUSION PROTEINS | 2020 |
|
RU2825292C1 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
| MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USE | 2020 |
|
RU2815388C2 |
| BINDING OF FUSED PROTEIN TO CD47 PROTEIN AND ITS USE | 2019 |
|
RU2787521C2 |
